Warnex completed its junior capital pool offering with the initial objective to acquire and develop businesses in the pharmaceutical sector.


Warnex acquired the assets of Les Laboratoires Biopharm Inc. and this transaction was considered the major transaction of the Corporation pursuant to the rules of the Alberta Stock Exchange (now the TSX Venture Exchange). These assets were the foundation for what is now Warnex Analytical Services, which offers quality control services, method development and validation, and contract R&D.


Warnex acquired the Genevision technology and Warnex Research was formed to focus on the development of this DNA detection technology.


Warnex created its Bioanalytical Services division, which conducts bioavailability and bioequivalence studies for clinical trials, as well as contract R&D.


Warnex Diagnostics was incorporated to commercialize the Company’s DNA detection technology.


Warnex Medical Laboratories was formed through the acquisition of the Clinical Laboratory assets of Adaltis Inc. The division specializes in human clinical testing, including the Prenatest® prenatal screening test and the Bioavailable Testoterone test.


Warnex acquired PRO-DNA Diagnostics, a genetic testing laboratory, and integrated it into the Warnex Medical Laboratories division.

Warnex Analytical Services Inc. acquired the MDS Pharma Services pharmaceutics business located in Blainville, Quebec, and named this new division Neopharm Laboratories. Neopharm Laboratories offers pharmaceutical analysis, traditional chemistry, microbiology, method development and validation, technology transfer, and stability studies.

Warnex decided to divest of the DNA detection technology business and focus on its profitable laboratory services divisions.


Warnex sold its pathogen detection business to AES Laboratoire, a leading French manufacturer and supplier of laboratory equipment and supplies.


Warnex acquired Molecular World Inc., a laboratory located in Thunder Bay, Ontario, specializing in human DNA identification including forensic DNA testing, and changed its name to Warnex PRO-DNA Services.


Warnex reorganized the operations of its subsidiary Warnex Analytical Services Inc., including the shutdown of its analytical laboratories located in Laval and the consolidation all of its analytical services at its Neopharm Laboratories facility located in Blainville.

Warnex sold its Medical Laboratories and PRO-DNA Services divisions to Gamma-Dynacare Medical Laboratories, one of Canada's largest providers of medical laboratory services.

Stock Quote

TSX: WNX   High: 0.05
Open: 0.05 Low: 0.03
Canadian $    Quotes are delayed.


2010 Annual Report (PDF: 643 Kb)
Corporate presentation (PDF: 3.43 Mb)
Fact sheet (PDF: 120 Kb)

Latest News

December 20, 2011
Warnex to Sell Its Analytical Services Division
December 9, 2011
Warnex Sells Its Medical and Forensic Testing Operations to Gamma-Dynacare and Reaches Repayment Agreement With Its Debentureholders